Drug intelligence / Profile preview

[211At]APA

Development stage
Preclinical
Lead developer
Telix Pharmaceuticals
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intrathecal, Intravenous
01

Overview

[211At]APA (also known as TLX102 or [211At]4-astato-L-phenylalanine) is an investigational targeted alpha-therapy (TAT) radiopharmaceutical being developed by Telix Pharmaceuticals. It is a small-molecule L-phenylalanine analogue radiolabeled with the alpha-emitting radionuclide astatine-211 (211At). The drug selectively targets and accumulates in tumor cells via the L-type amino acid transporter 1 (LAT1, also known as SLC7A5), which is highly overexpressed in various cancers, including glioblastoma and multiple myeloma. By delivering high-energy, short-range alpha radiation directly to cancer cells, [211At]APA aims to induce lethal DNA double-strand breaks while minimizing damage to surrounding healthy tissues. It is being developed for the treatment of glioblastoma, leptomeningeal disease, and multiple myeloma, and has received Orphan Drug Designation from the U.S. FDA for multiple myeloma and glioma.

Other names
[211At]4-astato-L-phenylalanine211At astato-L-phenylalanine211At-APA4-[211At]-L-phenylalanine4-[211At]astato-L-phenylalanineastatine-211 astato-L-phenylalanineastatine211 astato-L-phenylalanineastatine 211 astato-L-phenylalanine
02

Identity

Drug type
Radiopharmaceuticals
Originator
Osaka University
Modality
Small MoleculesAntibody-Based TherapeuticsAntibody-Radionuclide ConjugatesAlpha Emitters
Synonyms and codes
TLX102-Tx
03

Pharmacology

04

Development

IndicationHighest phaseStatus
glioblastoma, IDH-wildtypePreclinicalActive
multiple myeloma (MM)PreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

07

Patents & exclusivity

Patents
2

Patent families, expiry dates and exclusivities are in the full profile.

08

Competitive landscape

Drugs on the same target
20
Drugs in the lead indication
709

Lead indication: glioblastoma, IDH-wildtype

Most advanced in the lead indication

  1. bevacizumabApproved
  2. carmustineApproved
  3. floretyrosine (18F)Approved
  4. temozolomideApproved
  5. lacosamidePhase 4

Beyond the preview

Go deeper on [211At]APA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [211At]APA.

Work on [211At]APA? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call